22nd Century Group (XXII) Expected to Release Quarterly Earnings on Friday

22nd Century Group (NASDAQ:XXII) is expected to issue its Q2 2026 results before the market opens on Friday, August 14th. Analysts expect 22nd Century Group to announce earnings of ($6.00) per share and revenue of $7.48 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 13, 2026 at 8:00 AM ET.

22nd Century Group Stock Up 1.1%

NASDAQ:XXII opened at $4.40 on Wednesday. The firm’s 50 day simple moving average is $5.08 and its 200 day simple moving average is $47.96. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.67 and a quick ratio of 2.12. 22nd Century Group has a one year low of $3.61 and a one year high of $801.00. The company has a market cap of $2.29 million, a PE ratio of -0.00 and a beta of 0.65.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Weiss Ratings raised shares of 22nd Century Group from a “sell (e)” rating to a “sell (e+)” rating in a research note on Tuesday, July 28th. Wall Street Zen upgraded shares of 22nd Century Group to a “sell” rating in a report on Saturday, June 27th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

Hedge Funds Weigh In On 22nd Century Group

An institutional investor recently bought a new position in 22nd Century Group stock. Geode Capital Management LLC purchased a new position in shares of 22nd Century Group, Inc (NASDAQ:XXII) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 46,491 shares of the biotechnology company’s stock, valued at approximately $36,000. Geode Capital Management LLC owned about 9.12% of 22nd Century Group as of its most recent filing with the SEC. 18.06% of the stock is currently owned by hedge funds and other institutional investors.

About 22nd Century Group

22nd Century Group, Inc, founded in 1998 and headquartered in New York, is a plant biotechnology company that applies proprietary breeding and gene modulation technologies to tobacco, hemp and related plant species. The company’s core mission is to develop and commercialize plant-based solutions that address public health, consumer wellness and agronomic needs. Its flagship reduced nicotine tobacco platform is engineered to deliver significantly lower levels of nicotine than conventional tobacco products while retaining the sensory characteristics sought by adult smokers.

Through its branded reduced nicotine tobacco products, marketed under the NEXT Generation™ portfolio, and its GenCanna® subsidiary focused on hemp cultivation and cannabinoid extraction, 22nd Century serves both commercial markets and contract research clients.